Canadian astronaut Joshua Kutyrk is set to launch from Cape Canaveral, Florida on October 1, carrying advanced Canadian technology with him. Space travel poses health risks due to the effects of low gravity on the human body, including the potential formation of dangerous blood clots. To address this concern, NASA has partnered with Vancouver-based Response Biomedical to utilize innovative technology on the International Space Station (ISS).
The technology, known as Acute Care Testing in Space (ACTIS), is capable of detecting D-dimer levels in the blood, a crucial indicator of clot formation. This device, derived from Response Biomedical’s existing RAMP technology, offers quick and efficient blood testing for various conditions, including blood clots, heart attacks, and infectious diseases like COVID-19 and RSV.
NASA selected the Canadian Space Agency for this collaboration based on its expertise in health and life science research in space. The portability and rapid results of the ACTIS device make it a valuable tool not only for astronauts in space but also for medical professionals in remote communities on Earth.
CEO Taso Tsonis emphasized the importance of reliable and swift testing, highlighting the potential for ACTIS to support future space exploration missions to the moon and Mars. The selection of this Canadian technology for the ISS represents a significant achievement for Canada and showcases the country’s innovation and capabilities in the global space industry.